1. Industry Symposium World Congress Tissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5-8, 2012 Organized by TERMIS-AM and TERMIS-EU Industry Committees

2. TERMIS-AM Industry Committee Established 2009 Mission –Support commercialization in Tissue Engineering/Regenerative Medicine (TE/RM) Goals –Define and address obstacles/hurdles to product commercialization –Promote collaborations to build a viable TE/RM industry Members –Kiki B. Hellman, PhD; The Hellman Group. LLC; Chair –Timothy A. Bertram, DMV, PhD; Tengion –Peter C. Johnson, MD; Avery Dennison –Mark Van Dyke, PhD; Wake Forest University Health Sciences –Bill Tawil, PhD; Baxter Biosurgery 2

3. TERMIS-EU Industry Committee Established 2011 Mission –Motivate translation of academic research into commercial products, in Tissue Engineering/Regenerative Medicine (TE/RM) –Connect the scientific & clinical communities with TE/RM industries Goals –Give answers to critical questions, paving the road of TE/RM commercial translation, by key stakeholders, from past experiences –Promote academia–industry meetings & partnerships for more effective commercial translation in TE/RM Members –Yves Bayon, PhD; Covidien – Sofradim Production; Chair –Simon Ellison, MBA; NHS Blood & Transplant –John Barry, PhD; Baxter Innovations –Paul Stroemer, PhD, Reneuron –Chris Mason, PhD; University College of London –Alain Vertes, PhD; London Business School Sloan Fellow 3

4. 4 Partnership, the key for successful translation of Regenerative Products World CongressTERMIS Organized by TERMIS-AM and TERMIS-EU Industry Committees Industry Symposium

5. SESSION 1: “Commercialization of Regenerative Products: The Academe/Industry Partnership” World Congress Tissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5-8, 2012 Organized by TERMIS-AM and TERMIS-EU Industry Committees

6. Commercialization of Regenerative Products: The Academe/Industry Partnership Organizers: TERMIS-AM & TERMIS-EU Industry Committees Main Goals: to learn from past academia-industry collaborative experiences in TE/RM commercial development to enable academia and industry to understand how best to work together and identify individual collaborations that can rapidly move forward. 6

7. Commercialization of Regenerative Products: The Academe/Industry Partnership 7 9:05 – 9:20 Vienna/Austria - From a Strong Biomedical Tradition to a Future of Innovation and Patient Care Ehrlich H, Baxter Bioscience, Austria 9:20 – 9:40 Commercialization of regenerative medicine products: the academia-industry partnership Vertès A, London Business School, Sloan Fellowship, UK 9:40 – 10:00 Commercializing regenerative medicine therapeutics and sustaining a successful business Arshad A, Scientia Advisors, USA 10:00 – 10:15 Translating academic concepts to commercial medical products: A complex academic, industrial partnership Coury A, Consultant, USA 10:15 – 10:30 Successful translation of academic research using combinations of mesenchymal stromal cells with pharmaceutical agents for clinical applications in regenerative medicine Ghosh P, Mesoblast Ltd, Australia